|
Trial Name |
Description of Trial |
A5091005 |
A multi-centre, double-blind, randomized, parallel group, coronary artery intravascular ultrasound evaluation of the anti-atherosclerotic efficacy, safety and tolerability of fixed combination CP-529, 414/Atorvastatin, administered orally, once daily for 24 months compared with atorvastatin alone in subjects with angiographically documented CHD. |
|
ACTFAST |
Achieve cholesterol targets fast with atorvastatin stratified titration. |
|
ACTION |
A coronary disease trial investigating outcome with nifedipine GITS. |
AEGIS-I |
A phase 2b, multicenter, randomized, placebo-controlled, dose ranging study to investigate the safety and tolerability of multiple dose administration of CSL112 in subjects with acute myocardial infarction. |
AIM-HIGH |
Combination treatment regimen of simvastatin and extended release niacin (Niaspan®) versus a treatment regimen of simvastatin alone for the prevention of cardiovascular events. |
| AMPLIFY 056 | Apixaban vs. warfarin and Enoxaparin for acute DVT/PE. |
AMPLIFY EXT |
Apixaban vs placebo in patients who have completed 6 to 12 months of standard anticoagulant treatment for index event. |
APEX-AMI |
A multi-center, randomized, double-blind, parallel group, placebo controlled study of pexelizumab in patients with AMI undergoing primary PTCA. |
|
A-PLUS |
A phase II, two year efficacy trial to evaluate the effects of avasimibe on the progression of coronary atherosclerosis lesions as measured by intravascular ultrasound and coronary angiography. |
|
AQUAVIT |
A multicenter, randomized, placebo-controlled, double-blind trial to evaluate the effects of vasopressin V2 receptor antagonist (SR121462B) on clinical improvement in patients with severe chronic heart failure. |
|
ARISE |
Aggressive reduction of inflammation stops events reduction of vascular inflammation and coronary atherosclerosis with AGI 1067, a V-Protectant, reduces cardiovascular events in patients with coronary artery disease. |
ARTS HF |
A randomized, double-blind, double-dummy, multi-center study to assess safety and efficacy of BAY 94-8862 in subjects with emergency presentation at the hospital because of worsening chronic heart failure with left ventricular systolic dysfunction and either type 2 diabetes mellitus with or without chronic kidney disease or moderate chronic kidney disease alone versus eplerenone. |
|
ASSENT 1 |
Assessment of the Safety of a New Thrombolytic: TNK-tPA. |
|
ASSENT-4 |
Assessment of the safety and efficacy of a new treament strategy for acute myocardial. |
|
ATLAS |
Assessment of low dose vs. high dose lisinopril in treatment of congestive heart failure. |
AUGUSTUS (CV185316) |
An open-label, 2 x 2 factorial, randomized controlled, clinical trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin placebo in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention. |
AVANT-GARDE |
ACS patients treated with Aliskiren – Valsartan to reduce NT-proBNP. |
BICAR |
Clinical usefulness of sodium bicarbonate for the prevention of contrast induced nephropathy in patients undergoing a coronary procedure. |
| BIONICS | BioNIR ridaforolimus eluting stent In coronary stenosis. The purpose is to compare the efficacy (how well it works) and safety of the BioNIR to another drug eluting stent (DES) system that is already approved for use in humans, the Resolute. |
BLADE-PCI |
Biorest liposomal alendronate adminstration for diabetic patients undergoing drug-eluting stent percutaneous coronary intervention trial. |
BRIDGE |
Bridging anticoagulation in patients who require temporary interruption of Warfarin therapy for an elctive invasive procedure or surgery. |
CAIN-003 |
Correlation between coronary and carotid atherosclerosis disease and links with clinical outcomes. |
CANTOS |
A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP (CACZ885M2301). |
|
CAPTORS II |
A phase II, parallel group, randomized, sequential (blinded) dose-ranging and comparative clinical trial employing bolus pegylated staphylokinase (PEG-Sak) in patients with acute myocardial infarction. |
|
CARISA CVT 3033 |
A double-blind, randomized, stratified, placebo-controlled, parallel study of ranolazine SR at doses of 750 mg twice a day and 1000 mg twice a day in combination with other anti-anginal medications in patients with chronic stable angina pectoris. |
CARMELINA |
A multicenter, international, randomized, parallel group, double-blind, placebo-controlled cardiovascular safety and renal microvascular outcome study with LINAgliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk. |
CART-2 |
Safety and efficacy of AGI-1067 as an agent to prevent post-angioplasty restenosis and coronary atherosclerosis progression. |
CCTOP |
Canadian chronic total occlusion PCI network (CCTOP Network): a prospective observational database. |
CENTAURUS |
Comparison of the effects noted in the ApoB/ApoA-I ratio using rosuvastatin / atorvastatin in patients with acute coronary syndrome. |
CHARISMA |
Clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance. Ankle-brachial and ASA sub-studies. |
CHARM |
Candesartan cilexetil in heart failure assessment of reduction mortality and morbidity. |
 |
©Victoria Heart Institute Foundation
"Yesterday's research is tomorrow's best practice... Today's research leads to tomorrow's breakthroughs."